Clinical Trial Update: Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers [Phase 4]

View source ↗

Summary

Phase 4 trial of vortioxetine for major depressive disorder, cognition, and systemic inflammatory biomarkers in breast cancer patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: University of Miami | Conditions: Unipolar Major Depression, Stage I, II or III Breast Cancer | Phase 4 | Status: WITHDRAWN